Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT04495179
Title A Study of AZD4635 With Durvalumab and With Cabazitaxel and Durvalumab in Patients With mCRPC. (AARDVARC)
Recruitment Completed
Gender male
Phase Phase II
Variant Requirements No
Sponsors AstraZeneca

prostate adenocarcinoma


AZD4635 + Durvalumab

AZD4635 + Cabazitaxel + Durvalumab

Age Groups: adult | senior
Covered Countries USA | FRA | ESP | BEL

No variant requirements are available.